

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – May 20, 2005

NOTICE OF STATUS CHANGE

Study 1 will permanently close to accrual effective **May 19, 2005** at 4:30 p.m. (CST). The Study 1 accrual objective has been met.

Study 3 will open to accrual for Non-EIAC patients to the entire NCCTG membership at dose level 1D (150 mg OSI-774) effective **May 20, 2005**.

Please retain this notice with the protocol.